| Drug Name |
Apremilast |
| Drug ID |
BADD_D00156 |
| Description |
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.[A181216] |
| Indications and Usage |
Investigated for use/treatment in psoriasis and psoriatic disorders. |
| Marketing Status |
Prescription |
| ATC Code |
L04AA32 |
| DrugBank ID |
DB05676
|
| KEGG ID |
D08860
|
| MeSH ID |
C505730
|
| PubChem ID |
10151715
|
| TTD Drug ID |
D07ESC
|
| NDC Product Code |
65977-0119; 60219-1410; 60219-1744; 66406-0240; 66039-934; 70518-3155; 12658-0581; 69766-024; 59572-630; 65372-1204; 59572-631; 55513-369; 58032-2030; 59572-632; 53747-077; 55513-137; 59651-150; 53069-1040; 69766-010; 55513-485; 47621-306; 11722-062; 66406-0241; 46708-902; 65129-1383; 55111-993; 53069-1050; 73309-043; 49187-0757; 66406-0242 |
| Synonyms |
apremilast | Otezla | CC 10004 | CC10004 | CC-10004 |
